- Conference Article
- 10.1183/13993003.congress-2023.pa1680
Virucidal efficacy of cetylpyridinium chloride lozenges against coronavirus and influenza virus
- Sep 09, 2023
- Tina Peiter + 5 more +5
<b>Background:</b> With the rise in off-season patterns of viral infections, approaches to prevent respiratory tract infections and reduce the risk of antibiotic resistance are required. <b>Aims:</b> To determine the in vitro virucidal efficacy of antiseptic cetylpyridinium chloride (CPC) throat lozenges on coronavirus and influenza virus A. <b>Methods:</b> Sugar-containing (SC) and sugar-free (SF) CPC lozenges (Dolo-Dobendan®) were tested with the DIN EN 14476:2019–10 suspension test. Tablets were diluted 80% and incubated with bovine coronavirus (S379 Reims) or influenza virus A (H1N1; Brisbane/59/2007) under clean (0.3g/L bovine serum albumin) or dirty (tripartite soil load according to OECD, to mimic saliva secretion) conditions. A 10-min exposure (equivalent to tablet oral dissolution time) was used to calculate viral titre (TCID50/ml), with a reduction ≥4log10 (≥99.99%) considered sufficient. For coronavirus, large volume plating (LVP) was used as ≥4log10 was not possible due to cytotoxicity. <b>Results:</b> For influenza, after 5mins SC CPC exhibited 98.52% efficacy in clean (1.83±0.58) and dirty (1.83±0.54) conditions, and for SF 4log10 (≥99.99%) in clean (5.17±0.33) and dirty (4.00±0.00) conditions. Using LVP for coronavirus, after 10 mins SC CPC exhibited ≥99.9% efficacy in clean (3.43±0.45) and 99.8% in dirty (2.66±0.47) conditions, and SF CPC exhibited ≥99.99% efficacy in dirty (4.01±0.47) and 99.91% in clean (4.06±0.45) conditions. <b>Conclusion:</b> CPC lozenges demonstrated in vitro virucidal efficacy against coronavirus and influenza virus, which is relevant for the treatment of viral mouth and throat infections, and may be used as a preventative oral hygiene measure to reduce viral transmission risk.
Read more